8 completed, 2 not yet recruiting, 2 terminated, 2 withdrawn. 16 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 8, Not yet recruiting 2, Terminated 2, Withdrawn 2, Recruiting 1, Unknown 1 |
| Phase 2 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
Follow Finasteride: new trials by email Literature Review of Finasteride trials Research Report on Finasteride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial testosterone cypionate, finasteride, placebo injection - Spinal Cord Injury, Spinal Cord Injuries | Phase 2 / Phase 3 | Not yet recruiting | VA Office of Research and Development | 300 | 2027-10-01 | 2026-08-04 |
| Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia Finasteride 5 mg Tablet, single dose, Tamsulosin 0.4Mg Capsule - Benign Prostatic Hyperplasia | Phase 3 | Not yet recruiting | Il-Yang Pharm. Co., Ltd. | 660 | 2026-11-09 | 2026-10-13 |
| Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia Finasteride, Minoxidil - Androgenetic Alopecia | Phase 2 / Phase 3 | Unknown | Universitas Indonesia | 40 | 2023-05-01 | 2023-09-22 |
| Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia Finlândia Association + finasteride placebo, Minoxidil + finasteride - Androgenetic Alopecia | Phase 3 | Recruiting | EMS | 190 | 2023-02-02 | 2025-12-08 |
| Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH) GV1001 placebo, Proscar placebo - Benign Prostatic Hyperplasia (BPH) | Phase 3 | Completed | GemVax & Kael | 423 | 2019-10-30 | 2022-08-25 |
| Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia P-3074, Finasteride, P-3074 Vehicle - Alopecia, Androgenetic | Phase 3 | Completed | Polichem S.A. | 458 | 2016-08-02 | 2019-06-20 |
| H-36731: Finasteride in Management of Elevated Red Blood Cells Finasteride - ERYTHROCYTOSIS | Phase 3 | Withdrawn | Baylor College of Medicine | 2016-02-01 | 2019-12-16 | |
| Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2) Finasteride, Tamsulosin, Finasteride-matching placebo - Benign Prostatic Hyperplasia | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 1 | 2013-08-01 | 2018-08-29 |
| A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms Tadalafil, Placebo, Finasteride - Benign Prostatic Hyperplasia, Enlarged Prostate | Phase 3 | Completed | Eli Lilly and Company | 696 | 2010-09-01 | 2013-02-27 |
| On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP) Finasteride, Placebo - Benign Prostatic Hyperplasia | Phase 3 | Withdrawn | University of Alberta | 2008-02-01 | 2017-10-30 | |
| A Trial of PROSCAR (Finasteride) Versus Placebo in Men With an Initial Negative Prostate Biopsy Finasteride, Placebo - Enlarged Prostate | Phase 3 | Completed | University Health Network, Toronto | 19 | 2008-02-01 | 2015-12-09 |
| Minimally Invasive Surgical Therapy for BPH Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation (TUNA) Therapy, Finasteride and Alfuzosin - Benign Prostatic Hyperplasia | Phase 3 | Terminated | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 49 | 2004-04-01 | 2010-01-14 |
| Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer. Flutamide, Finasteride, Placebo - Prostate Cancer, Prostatic Intraepithelial Neoplasia | Phase 2 / Phase 3 | Completed | Ente Ospedaliero Ospedali Galliera | 125 | 2004-01-01 | 2024-09-19 |
| A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140) MK0906, finasteride / Duration of Treatment: 48 weeks, Comparator: placebo / Duration of Treatment: 48 weeks - Benign Prostatic Hyperplasia | Phase 3 | Completed | Organon and Co | 600 | 2004-01-01 | 2024-08-15 |
| Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) MK0906, finasteride / Duration of Treatment : 48 Weeks, Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks - Androgenetic Alopecia | Phase 3 | Completed | Organon and Co | 355 | 1998-03-01 | 2022-02-17 |
| Medical Therapy of Prostatic Symptoms Doxazosin, Finasteride, Doxazosin placebo - Prostatic Hyperplasia, Prostatic Hypertrophy, Benign | Phase 3 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 3407 | 1995-12-01 | 2018-09-28 |
Prostatic Hyperplasia (8) · Alopecia (4) · Bone Diseases (1) · Bone Resorption (1) · Central Nervous System Diseases (1) · Endocrine System Diseases (1) · Genital Diseases (1) · Genital Diseases, Male (1) · Gonadal Disorders (1) · Hypogonadism (1) · Male Urogenital Diseases (1) · Motor Activity (1) · Musculoskeletal Diseases (1) · Nervous System Diseases (1) · Polycythemia (1)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Organon and Co (2) · Baylor College of Medicine (1) · EMS (1) · Eli Lilly and Company (1) · Ente Ospedaliero Ospedali Galliera (1) · GemVax & Kael (1) · Il-Yang Pharm. Co., Ltd. (1) · Merck Sharp & Dohme LLC (1) · Polichem S.A. (1) · Universitas Indonesia (1) · University Health Network, Toronto (1) · University of Alberta (1) · VA Office of Research and Development (1)
United States (5) · Canada (3) · Belgium (2) · Brazil (2) · Germany (2) · Italy (2) · Russia (2) · Argentina (1) · France (1) · Greece (1) · Hungary (1) · Indonesia (1) · Mexico (1) · Poland (1) · South Korea (1)
Andrea De Censi, MD (1) · Antonio Finelli, MD MSc FRCSC (1) · Claus Roehrborn (1) · E. David Crawford (1) · Eric Massana, MD (1) · Gary J. Miller (1) · Gerald L. Andriole (1) · Harris E. Foster (1) · Harry S. Clarke (1) · Herbert Lepor (1) · Howard Evans, MD (1) · Joe W. Ramsdell (1) · John P. Foley (1)
PMID 11796283, PMID 12689743, PMID 14681504, PMID 17196507, PMID 25353053, PMID 40683564
U01DK046472 (1), U01DK060817 (1)